Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

Core Insights - Repligen (RGEN) reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.42 per share, and showing an increase from $0.43 per share a year ago, resulting in an earnings surprise of +9.52% [1] - The company achieved revenues of $188.81 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.18% and increasing from $154.87 million year-over-year [2] - Repligen has outperformed consensus EPS estimates three times in the last four quarters and has also topped consensus revenue estimates three times during the same period [2] Future Outlook - The sustainability of Repligen's stock price movement will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.51 on revenues of $193.62 million, while the estimate for the current fiscal year is $1.69 on revenues of $726.41 million [7] - The Zacks Rank for Repligen is currently 4 (Sell), indicating expectations of underperformance in the near future due to unfavorable estimate revisions prior to the earnings release [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Repligen belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]